Results 11 to 20 of about 22,482 (226)

Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe [PDF]

Ophthalmology and Therapy
Introduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).
Arianna Peyla, Matteo Bonanata, Martina Pache, Michele Clerici, Moreno Menghini, Gabriela Grimaldi, Giulio Volpe   +6 more
doaj   +2 more sources

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study [PDF]

Ophthalmology and Therapy
Introduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases.
Giulio Volpe, Matteo Bonanata, Arianna Peyla, Ludovico Ruscitti, Veronika Eggarter, Martina Pache, Arianna Paris, Moreno Menghini, Gabriela Grimaldi   +8 more
doaj   +2 more sources

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products [PDF]

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
ABSTRACT Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases.
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch   +10 more
wiley   +2 more sources

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab

International Medical Case Reports Journal, 2018
Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Athina Pallikari, Constantine D Georgakopoulos Department of Ophthalmology, University of Patras, Patras, Greece Purpose: To report the 12-month outcomes of a patient switching from intravitreal ...
Makri OE, Tsapardoni FN, Plotas P, Pallikari A, Georgakopoulos CD   +4 more
doaj   +1 more source

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj   +1 more source

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +2 more sources

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj   +1 more source

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema [PDF]

JAMA ophthalmology
This randomized clinical trial investigates the efficacy and safety of aflibercept biosimilar MYL-1701P compared with reference aflibercept for the treatment of diabetic macular edema (DME).
S. Bressler, Abhijit Barve, Prasanna C. Ganapathi, Katrin Beckmann, R. Apte, Dennis M. Marcus, Kristīne Baumane, S. Agarwal, P. Oleksy, D. Reichstein, Sunil S. Patel, Jan Ernest, R. Dégi, Vishali Gupta, Genichiro Kishino, Motohiro Kamei, Subramanian Loganathan   +16 more
semanticscholar   +2 more sources

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês   +11 more
core   +1 more source